Caisse DE Depot ET Placement DU Quebec Decreases Stake in Pfizer Inc. $PFE

Key Points

• Caisse DE Depot ET Placement DU Quebec has reduced its stake in Pfizer Inc. by 32.8%, selling 922,400 shares and owning a total of 1,893,722 shares worth approximately $47.99 million.
• Several institutional investors, including Pacer Advisors Inc. and Goldman Sachs, have significantly increased their positions in Pfizer, showcasing 68.36% of the stock currently owned by hedge funds and other institutional investors.
• Pfizer reported earnings of $0.78 EPS in its latest quarter, exceeding expectations, and it announced a quarterly dividend of $0.43 per share with a yield of 6.8%.

Caisse DE Depot ET Placement DU Quebec reduced its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 32.8% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,893,722 shares of the biopharmaceutical company's stock after selling 922,400 shares during the period. Caisse DE Depot ET Placement DU Quebec's holdings in Pfizer were worth $47,987,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the stock. Pacer Advisors Inc. boosted its position in shares of Pfizer by 856.8% in the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock worth $508,164,000 after buying an additional 17,957,928 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Pfizer in the 1st quarter worth about $389,861,000. Starboard Value LP purchased a new stake in shares of Pfizer in the 4th quarter worth about $407,730,000. Goldman Sachs Group Inc. boosted its position in shares of Pfizer by 51.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock worth $670,407,000 after buying an additional 9,041,990 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in shares of Pfizer by 307.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock worth $254,574,000 after buying an additional 7,581,030 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Citigroup boosted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Redburn Atlantic decreased their price objective on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 30th. UBS Group upped their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Leerink Partners reduced their target price on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a report on Wednesday, April 30th. Finally, Bank of America upped their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $28.12.

Pfizer Trading Down 2.8%

NYSE PFE opened at $25.15 on Tuesday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The company has a 50-day moving average of $24.72 and a 200-day moving average of $24.39. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company has a market cap of $142.99 billion, a P/E ratio of 13.38, a P/E/G ratio of 0.92 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the prior year, the company posted $0.60 EPS. The company's quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.